Results 51 to 60 of about 4,150 (157)

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors

CA: A Cancer Journal for Clinicians, Volume 74, Issue 4, Page 359-367, July/August 2024.
Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to ...
Aman Chauhan, Kelley Chan, Thorvardur R. Halfdanarson, Andrew M. Bellizzi, Guido Rindi, Dermot O’Toole, Phillip S. Ge, Dhanpat Jain, Arvind Dasari, Daniel A. Anaya, Emily Bergsland, Erik Mittra, Alice C. Wei, Thomas A. Hope, Ayse T. Kendi, Samantha M. Thomas, Sherlonda Flem, James Brierley, Elliot A. Asare, Kay Washington, Chanjuan Shi   +20 more
wiley   +1 more source

Nowotwory neuroendokrynne trzustki — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych) [PDF]

, 2014
We present revised diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine neoplasms (PNENs) proposed by the Polish Network of Neuroendocrine Tumours.These guidelines refer to biochemical (determination of specific and ...
Andrysiak-Mamos, Elżbieta, Bednarczuk, Tomasz, Blicharz-Dorniak, Jolanta, Bolanowski, Marek, Cichocki, Andrzej, Deptała, Andrzej, Foltyn, Wanda, Handkiewicz-Junak, Daria, Hartleb, Marek, Hubalewska-Dydejczyk, Alicja, Jarząb, Michał, Jeziorski, Arkadiusz, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kos-Kudła, Beata, Kowalska, Aldona, Król, Robert, Królicki, Leszek, Kunikowska, Jolanta, Kuśnierz, Katarzyna, Lampe, Paweł, Lange, Dariusz, Lewczuk, Anna, Londzin-Olesik, Magdalena, Majewski, Przemysław, Marek, Bogdan, Mełeń-Mucha, Gabriela, Nasierowska-Guttmejer, Anna, Nowak, Andrzej, Nowakowska-Duława, Ewa, participants of the Consensus Conference (affiliations at the end of this section):, Other, Patkowski, Waldemar, Pilch-Kowalczyk, Joanna, Rosiek, Violetta, Ruchała, Marek, Rudzki, Sławomir, Ruszniewski, Philippe, Rydzewska, Grażyna, Sowa-Staszczak, Anna, Starzyńska, Teresa, Steinhof-Radwańska, Katarzyna, Strzelczyk, Janusz, Zajęcki, Wojciech, Zdunowski, Piotr, Zemczak, Anna, Ćwikła, Jarosław B.   +45 more
core   +2 more sources

Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial

Cancer Medicine, Volume 13, Issue 8, April 2024.
Abstract Background More than half of neuroendocrine tumor (NET) patients will experience liver metastasis, and interventional therapy represented by transarterial embolization (TAE) is the main local treatment method. Surufatinib is recommended as a standard systemic treatment for advanced NETs. The efficacy and safety of surufatinib combined with TAE
Ruizhen Li, Xiaofen Li, Xin You, Minggang Su, Yuzhi Liu, Nengwen Ke, Dan Cao   +6 more
wiley   +1 more source

Comparison of epidural infusion versus intrathecal morphine block as part of enhanced recovery after open pancreatoduodenectomy

Journal of Surgical Oncology, Volume 129, Issue 5, Page 869-875, April 2024.
Abstract Background and Objectives The accepted approach to pain management following open pancreatoduodenectomy (PD) remains controversial, with the most recent enhanced recovery after surgery (ERAS) protocols recommending epidural anesthesia (EA). Few studies have investigated intrathecal (IT) morphine, combined with transversus abdominis plane (TAP)
Jessica C. El‐Mallah, Alicia C. Greene, Taylor J. Clegg, Sejal J. Shah, Saif N. El‐Mallah, Charles C. Vining, Matthew E. B. Dixon, June S. Peng   +7 more
wiley   +1 more source

Diagnosing Multiple Endocrine Neoplasia Type1 in a Resource Limited Setting: A Case Report of Pancreatic Neuroendocrine Tumor Causing Gastric Outlet Obstruction [PDF]

, 2023
Gastric outlet obstruction (GOO) is a narrowing of the pyloric outlet of the stomach due to benign or malignant disease processes. Pancreatic neuro endocrine tumor (NET) as a cause of GOO is a rare etiology.
Ruhama Imana (MD)
core   +1 more source

The Early Diagnosis of Gastrinoma

Annals of Surgery, 1982
Despite the increasing awareness of gastrinoma and its lethal peptic ulcer sequelae, the diagnosis is often initially missed or made as a terminal event. The authors screened all patients with peptic ulcer symptoms serious enough to warrant hospital admission or those associated with diarrhea, nephrolithiasis, hypercalcemia, or pituitary abnormality ...
Irvin M. Modlin, Anthony Sank, D. Albert, Bernard M. Jaffe   +3 more
openaire   +4 more sources

A case of recurrent gastrinoma in the liver with a review of "primary" hepatic gastrinomas

Case Reports, 2009
The present report concerns a patient with a malignant gastrin-producing neuroendocrine tumour (ie, Zollinger-Ellison syndrome) with recurrent hepatic gastrinomas, in whom no gastrinoma in the duodenum, pancreas or other extrahepatic sites could be identified despite the use of multiple, repeatedly performed imaging and exploration techniques over the ...
Hein W. Verspaget, Cornelis B.H.W. Lamers, Patricia Kuiper, Izak Biemond   +3 more
openaire   +4 more sources

Neoplasias endocrinas múltiples. desde el laboratorio al paciente [PDF]

, 2013
ResumenLas neoplasias endocrinas múltiples (NEM) tipo 1 y 2 son enfermedades genéticas heredadas en forma autosómica dominante. Las principales manifestaciones clínicas en NEM1 incluyen tumores paratiroideos, hipofisiarios y gastroenteropancreáticos.
Nelson Wohllk, G., René Diaz, T.
core   +2 more sources

Misdiagnosed gastrinoma: A case report

Oncology Letters, 2014
Gastrinoma is most commonly located in the gastrinoma triangle (comprising of the duodenum, pancreas and bile ducts) or in the adjacent lymph nodes. Due to the low mortality rate, it is often misdiagnosed as other diseases with similar clinical characteristics, such as a solid pseudopapillary tumor of the pancreas (SPTP).
Wei Wang, Yang Lv, Qi‑Kai Sun, Hang‑Cheng Zhou, Wei-Dong Jia, Ge‑Liang Xu, Ji‑Hai Yu, Jin‑Liang Ma   +7 more
openaire   +4 more sources

Gastrinoma: State of the Art

Cancer Control, 1997
Background The Zollinger-Ellison syndrome, implicating a gastrinoma, was first recognized as a disease entity in 1955. At that time, total gastrectomy was the most common treatment approach. Advances in several aspects of the disease have occurred since that time. Methods The authors reviewed the changes that have developed since 1955 in the diagnosis,
Peter J. Fabri, Constantine A. Godellas, Constantine A. Godellas   +2 more
openaire   +3 more sources